Skip to main content


Latest articles

26-10-2021 | Diabetes | News | Article

Statin treatment linked to increased likelihood of diabetes progression

Study findings published in JAMA Internal Medicine show that treatment initiation with statins is associated with an elevated risk for diabetes progression.

25-10-2021 | Diabetes | News | Article

CGM discontinuation negatively affects TIR in people with type 2 diabetes

Discontinuing continuous glucose monitoring leads to the loss of approximately half of the additional time in glycemic range accrued during its use among people with type 2 diabetes, MOBILE study data show.

22-10-2021 | Diabetes | News | Article

SGLT2 inhibitor cost-effectiveness feasible in low-, middle-income countries

Reducing the cost of SGLT2 inhibitors by around 17% would make them cost-effective for use in people with type 2 diabetes in low- and middle-income countries, study findings indicate.

21-10-2021 | Diabetes | News | Article

Kidney disease in absence of CVD a red flag for people with type 2 diabetes

Chronic kidney disease is strongly associated with risk for cardiovascular disease events even in the absence of pre-existing vascular disease among people with type 2 diabetes, say researchers.

20-10-2021 | Diabetes | News | Article

Insulin sensitivity may impact partial remission phase of early type 1 diabetes

Insulin sensitivity may be associated with the likelihood of partial remission in children and adolescents newly diagnosed with type 1 diabetes, regardless of C-peptide levels and BMI, research suggests.

19-10-2021 | Diabetes | News | Article

Tirzepatide preferable to glargine when OADs fail in SURPASS-4

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

18-10-2021 | Diabetes | News | Article

Glycemic control may affect COVID-19 vaccination effectiveness in type 2 diabetes

Response to vaccination against SARS-CoV-2 may be impaired in people with type 2 diabetes and poor glycemic control, but potentially improved if glucose levels are controlled, say researchers.

15-10-2021 | Diabetes | News | Article

Dapagliflozin benefits for eGFR, albuminuria revealed

Dapagliflozin slows the long-term decline in estimated glomerular filtration rate, and reduces albuminuria, particularly in people with type 2 diabetes, report the DAPA-CKD investigators.

14-10-2021 | Diabetes | News | Article

Real-world data highlight universal benefits of flash glucose monitoring

Flash glucose monitoring improves glycemic control and reduces diabetic ketoacidosis rates across nearly all age, sex, and sociodemographic strata, regardless of insulin pump use, according to UK observational data.

13-10-2021 | Diabetes | News | Article

Liraglutide add-on may offer better control than OADs in type 2 diabetes

The addition of liraglutide rather than extra oral antidiabetic drugs may offer more sustained glycemic control for people with type 2 diabetes who have inadequate control with metformin, suggest findings of the international LIRA-PRIME study.

12-10-2021 | Diabetes | News | Article

DiRECT insights highlight ‘ongoing struggle’ of maintaining weight loss

Many participants of DiRECT found reintroduction of food and subsequent weight-loss maintenance to be more challenging than the 800 calorie total meal replacement phase, the investigators report.

11-10-2021 | Diabetes | News | Article

One size does not fit all for glucose control after stroke

The optimal glycemic targets in people with diabetes who have had a stroke may vary according to the stroke subtype, a registry study suggests.

08-10-2021 | Diabetes | News | Article

Fully closed-loop insulin delivery not yet a match for precise carb counting

A dual-hormone fully closed-loop system did not demonstrate non-inferiority to a hybrid system in a randomized trial, despite producing a high time in range, report the researchers.

07-10-2021 | Diabetes | News | Article

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

05-10-2021 | Diabetes | News | Article

Nerve fiber dysfunction evident early in type 1 and type 2 diabetes course

Both small and large nerve fiber impairment can be detected among people with well-controlled recent-onset type 1 or type 2 diabetes, and may regress with time, shows German research presented at the virtual 57th EASD Annual Meeting.

05-10-2021 | Diabetes | News | Article

Semaglutide treatment may reduce systemic inflammation

Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.

05-10-2021 | Diabetes | News | Article

Socioeconomic inequalities impact multiple aspects of diabetes care

Data from Scotland show that low socioeconomic status increases people’s risk for developing type 2 diabetes, while for those with type 1 diabetes it increases time spent with complications and reduces life expectancy.

05-10-2021 | Diabetes | News | Article

Omnipod DASH benefits confirmed in real-world study

Children and adults with type 1 diabetes achieve significant reductions in glycated hemoglobin and hypoglycemic events during their first 90 days of using the Omnipod DASH insulin pump system, show real-world data.

04-10-2021 | Diabetes | News | Article

Real-world data show comparable benefits for second-generation insulins in type 2 diabetes

Insulin-naïve people with type 2 diabetes initiating the second-generation basal insulins glargine 300 or degludec 100 experience similar improvements in glycated hemoglobin levels, show data from the real-world RESTORE-2 study.

04-10-2021 | Diabetes | News | Article

SoliMix trial supports iGlarLixi for type 2 diabetes

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.